Biotech vs. Shorts Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech vs. Shorts

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Neuroguy who wrote (364)	2/12/2000 12:14:00 PM
From: scaram(o)uche	of 427

>> They have no blockbuster drugs (Perceptin - I think not). << Why will it not be effective for attention-promotion in aging disorders/dementia? Why will it not be effective for narcolepsy and other sleep disorders? Why will it not be effective for certain obesity applications? Why will it not be effective for attention deficit disorder in adults? I'm not going to represent that I have relevant expertise. However, I've talked to many who appear to have such, and they're impressed. Rather than just taking a shot, please provide some rationale, so that we can all profit from your experience. It's a very highly leveraged business plan as represented, and there's a ton of data pointing to marked activity for Perceptin and other H3-receptor antagonists in preclinical models. Please tell us why the representation is deceiving. If you can, all SI shareholders will appreciate the op to make an early exit. Thanks.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next